Havey Adam 4

4 · Emergent BioSolutions Inc. · Filed Mar 3, 2021

Form 4

Period: 2021-03-01

EVP, BioDefense Division

Transactions

Exercise/Conversion
Common Stock
2021-03-01$30.63/sh+17,134$524,814→ 55,324 total
Sale
Common Stock
2021-03-01$99.62/sh−17,134$1,706,889→ 38,190 total
Exercise/Conversion
Common Stock
2021-03-01$49.64/sh+20,145$999,998→ 58,335 total
Sale
Common Stock
2021-03-01$99.02/sh−20,145$1,994,758→ 38,190 total
Exercise/Conversion
Employee Stock Options (Right to Buy)
2021-03-01$99.62/sh−17,134$1,706,889→ 0 total
Exercise: $30.63Exp: 2024-02-27→ Common Stock (17,134 underlying)
Exercise/Conversion
Employee Stock Options (Right to Buy)
2021-03-01$99.02/sh−20,145$1,994,758→ 0 total
Exercise: $49.64Exp: 2025-02-26→ Common Stock (20,145 underlying)

Footnotes (4)

[F1]The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Mr. Havey.
[F2]The price reported is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $98.05 to $100.25.
[F3]The price reported is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $98.01 to $99.99.
[F4]Vests in three equal installments beginning on the day prior to the anniversary date of the grant.

Documents

1 file